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ABSTRACT 
An enhanced understanding of the pathophysiology of depression would facilitate the 
discovery of new efficacious medications. To this end, we examined hippocampal 
transcriptional changes in rat models of disease and in humans to identify common disease 
signatures by using a new algorithm for signature-based clustering of expression profiles. 
The tool identified a transcriptomic signature comprising 70 probesets able to discriminate 
depression models from controls in both Flinders Sensitive Line and Learned Helplessness 
animals. To identify disease-relevant pathways, we constructed an expanded protein 
network based on signature gene products and performed functional annotation analysis. 
We applied the same workflow to transcriptomic profiles of depressed patients. Remarkably, 
a 171-probesets transcriptional signature which discriminated depressed from healthy 
subjects was identified. Rat and human signatures shared the SCARA5 gene, while the 
respective networks derived from protein-based significant interactions with signature genes 
contained 25 overlapping genes. The comparison between the most enriched pathways in 
the rat and human signature networks identified a highly significant overlap (p-value: 
3.85x10-6) of 67 terms including ErbB, neurotrophin, FGF, IGF, and VEGF signaling, immune 
responses and insulin and leptin signaling. In conclusion, this study allowed the identification 
of a hippocampal transcriptional signature of resilient or susceptible responses in rat MDD 
models which overlapped with gene expression alterations observed in depressed patients. 
These findings are consistent with a loss of hippocampal neural plasticity mediated by 
altered levels of growth factors and increased inflammatory responses causing metabolic 
impairments as crucial factors in the pathophysiology of MDD. 
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INTRODUCTION 
About one third of major depressive disorder (MDD) patients do not respond or respond 
only partially to available treatments (Mrazek et al, 2014). The challenge to discover new 
therapies is increased by the incomplete understanding of the pathophysiological bases of 
the disease. Compelling evidence supports the notion that disease onset is caused by genetic 
predisposition and environmental triggering challenges, principally stress (McEwen, 2017). 
The identification of the genes has proven difficult (CONVERGE consortium, 2015; Flint and 
Kendler, 2014; Major Depressive Disorder Working Group of the Psychiatric GWAS 
Consortium et al, 2013), but a recent study identified 17 independent loci (Hyde et al, 2016). 
Stressful experiences during childhood are considered as particularly critical for determining 
a long-term increase in the risk to develop depressive symptoms.  
Research using animal models has provided a crucial contribution to the understanding of 
MDD neurobiology. The Flinders Sensitive Line (FSL) is a strain that phenotypically presents a 
number of depression symptoms in comparison with the Flinders Resistant Line (FRL) 
controls. FSL rats show increased immobility in the forced swim test, reduced activity in 
novel open-field behaviors, decreased appetite and weight loss, sleep disturbances and 
neurochemical abnormalities, similar to those found in humans (Overstreet et al, 2005). In 
the learned helplessness (LH) model, the rats are exposed to uncontrollable, unpredictable, 
and unavoidable stress and subsequently tested for a deficit in acquiring an escape task. This 
helplessness response is induced only in some of the animals (termed LH rats and compared 
with the non-responding nLH rats), thereby modeling the hypothesis of variable 
predisposition for depression in different subjects (Vollmayr and Gass, 2013). With the aim 
of reproducing the impact of childhood adverse events, the maternal separation (MS) 
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paradigm was applied to model gene x environment interactions (Piubelli et al, 2011). Since 
psychopathology in humans has mostly been linked to stressful experiences of social nature, 
social defeat (SD) models stress are considered ethologically valid. In this model, the 
experimental rats are introduced into the territory of an aggressive male conspecific that 
attacks and defeats them, inducing long-lasting behavioral and endocrine effects (Buwalda 
et al, 2005). Since MDD is heterogeneous, it has been suggested that different animal 
models may help to identify both the diversity of the causes and the shared mechanisms 
underlying common symptoms of the human disease (Akil et al, 2018). This approach has 
allowed the identification of common transcriptional dysregulations between rodent models 
and MDD patients (Hervé et al, 2017; Labonté et al, 2017; Wingo et al, 2018). 
The objective of this study was to examine gene expression changes in rat models of 
depression and in humans and identify common signatures of disease. The transcriptional 
analysis was carried out in the hippocampus since structural and functional neuroimaging 
studies have revealed that MDD is accompanied by structural changes in this brain region 
(Sheline et al, 2002). In the hippocampus, stress exposure induces an allostatic process 
aimed at reinstating homeostasis by triggering a plasticity response that causes changes in 
neural architecture as well as in synaptic functions. In MDD, a stress-related disorder, an 
allostatic overload impairs adaptive plasticity responses, causing dendritic shrinkage and loss 
of spines and suppressing neurogenesis in the dentate gyrus (McEwen et al, 2015). These 
dysregulations are assumed to sustain hippocampal structural alterations observed in 
patients and evidence is available that they can be reproduced in the hippocampus of animal 
models of disease (McEwen et al, 2015). To increase the sensitivity of the analysis we used a 
recently introduced algorithm for signature-based clustering of expression profiles to 
identify a common transcriptional signature in different models of MDD, with subsequent 
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functional annotation by means of network-based analysis. Next, we applied the same 
workflow to transcriptional data generated in depressed patients and discovered a 
transcriptional signature able to discriminate disease versus control groups. Finally, we 
compared the findings obtained in the animal models with the human transcriptional 
signature to evaluate the relevance of the results for understanding the pathophysiological 
basis of MDD. We discovered that a common transcriptional signature discriminating LH and 
FSL rats from controls could be identified and that the main affected cellular pathways 
converged on growth factors as well as metabolic and inflammatory pathways implicated in 
sustaining neural plasticity, which were similarly influenced in depressed patients.  
MATERIALS AND METHODS 
Animals 
FSL and FRL male rats (n=38 and 22) were from colonies maintained in the animal facility at 
the Karolinska Institutet. In SD experiments, Long Evans rats (400-450g) were purchased 
from Harlan, U.S.A.; Sprague Dawley female (250-300g) and male rats (300-350g) were from 
Charles River, Italy. In LH experiments, male Sprague Dawley rats weighed 200-240g (Janvier, 
France). In chronic mild stress (CMS) experiments, male Wistar rats weighing 220-230g were 
used (Charles River, Germany). Animals were housed in standard cages and maintained at a 
constant temperature of 22±1° C and 12-h light-dark cycle. Food and water were freely 
available.  
Animal handling and experimental procedures were performed in accordance with the 
European Community Council Directive 86/609/EEC and were approved by local authorities. 
All efforts were made to minimize animal distress and to reduce the numbers of animals 
used.  
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Behavioral procedures 
MS was performed as previously published (Piubelli et al, 2011). Briefly, pups assigned to the 
separation procedure (MS group, 20 rats within the FSL group) were separated from the dam 
as a litter for 180min. Control rats were left undisturbed, except for routine cleaning.  
Forced-swim test consisted of two exposures to a water tank that does not permit escape 
(Blaveri et al, 2010). During the first exposure, rats were placed into the tank for 15min. The 
second exposure occurred 24h afterwards and lasted 5min during which rats behaviour was 
videotaped and subsequently scored by a trained experimenter blind to the animal 
experimental group. Immobility time, expressed as duration (s), was analysed.  
For SD, a resident-intruder protocol was followed (Carboni et al, 2006). Briefly, Long Evans 
male rats were used as dominant rats. Experimental subjects were Sprague-Dawley male 
rats (n=10) that served as intruders by being transferred into the resident rat cage. Following 
the attack by the dominant leading to the defeat of the intruder, experimental subjects were 
physically isolated and left in visual, auditory and olfactory contact with the dominant for the 
following 30min. Intruders were randomly exposed to different resident animals for 21 days. 
Control rats (n=10) were introduced in a novel clean cage, without resident rat with the 
same protocol.  
Learned Helplessness (LH) consisted of 20min of inescapable foot-shock in a 40min session. 
24h after inescapable shock, animals were tested for learned helplessness behaviour. 
Testing consisted of 15 trials of 0.8mA current lasting 60s each with 24s inter-trial time. 
Current was accompanied by a light clue to facilitate detection of the lever and animals were 
able to terminate the current by pressing the lever. Nine rats with more than 10 failures to 
terminate the current were selected for the experiment as LH; 8 rats with less than 5 failures 
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were selected as the nLH controls. Antidepressant treatment with 25 mg/kg escitalopram 
(ESC) was carried out for 7 days.  
Chronic mild stress (CMS) was performed as previously published (Luoni et al, 2015); the 
paradigm consisted in exposure to a chronic mild stress procedure for 7 weeks, while control 
rats were housed in separate rooms and had no contact with the stressed animals.  
Detailed procedures are described in Supplementary Methods.  
Gene expression analysis 
Rat samples were processed as reported in (Blaveri et al, 2010) and in (Luoni et al, 2015). 
The present study compared publicly available hippocampal gene expression profiles 
measured in post-mortem tissue from subjects with MDD and matched unaffected controls 
(n=19/group). The data have been made available to researchers world-wide and are 
available from the Gene Expression Omnibus (accession ID:GSE53987; 
www.ncbi.nlm.nih.gov/geo). Human microarray data were generated by hybridization to 
Affymetrix Human Genome U133 Plus 2.0 arrays 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53987). Additional details are 
available in Supplementary Methods. 
Bioinformatics 
Transcriptional signatures were identified by means of an enhanced version of the rank-
based classification method previously published (Lauria, 2013; Lauria et al, 2015). In the 
enhanced version used here, the original classification method has been extended with a 
genetic algorithm optimizer that automatically selects the method parameters (signature 
length and feature selection stringency) to maximize the accuracy of subject classification. In 
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the case of the transcriptional signature reported in Table 1, rat samples coming from the 
three considered datasets (FSL, LH and SD) have been merged together in order to obtain 
one single dataset to which the classification algorithm has been applied. The classification 
algorithm was then trained to perform a dichotomous classification, specifically to accurately 
classify control subjects, which consist of all the control samples from all the datasets, from 
the class of diseased ones, which includes all FSL, LH and SD rats. A training version of the 
merged dataset was obtained by excluding samples difficult to classify, specifically FSL with 
MS, which share the FSL group as their controls, and SD rats, which were not separated into 
susceptible and resilient responders. The signatures resulting from the training were then 
used to run the algorithm in validation mode and to perform a classification on the complete 
dataset. In the case of the human transcriptional signature reported in Table 2, the 
classification algorithm has been applied to distinguish control samples from subjects with 
MDD without any pre-processing of the dataset.  
To facilitate the interpretation of the biological processes underlying the phenomenon under 
investigation, we characterized the list of genes constituting the transcriptional signature by 
means of a network analysis technique implemented in NetWalker. Orthologs of the rat 
signature genes were obtained using Biomart (www.biomart.org). We used the protein-
protein interaction network in the Netwalker suite (which includes HPRD, BIND, HomoMINT, 
Gene and IntAct) as background network, the genes included in the signature as the set of 
genes of interest, and the negative log2 of the p-values computed during the probe filtering 
step in the signature identification algorithm (Kruskal-Wallis test) as gene scores. The 
NetWalker output consisted of a list of interactions of the background network and their 
scores as computed by the algorithm. We then extracted the connected sub-network 
containing all interactions above the empirically-selected threshold (n=543 selected 
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interactions for the rat and n=448 for the human). The final list of genes was given by the 
genes included in such a sub-network (n=272 genes for the rat and n=274 for the human). 
The gene lists obtained from the transcriptional signature and from the network enrichment 
analysis were used to extract the most representative GO Biological Process terms (i.e. 
among statistically significant enriched terms, we manually discarded the most generic 
biological processes deemed as too general to provide specific information; the complete 
lists are reported in Tables S1, S3, S6, S8). For identifying and visualizing enriched GO terms, 
we used GOrilla and REVIGO tools. Pathway analysis was performed using ConsensusPathDB. 
Hypergeometric distribution with an adjusted p-value (FDR) threshold of 0.001 was applied 
to test GO and pathway enrichments, using HPRD gene list as reference background.  
Detailed procedures are described in Supplementary Methods. 
Comparison between pathway enrichment of the rat and human network lists 
The pathway lists resulting from the enrichment analysis of the rat network list were ranked 
based on the negative logarithm of the p-value computed by the ConsensusPathDB tool. The 
same ranking operation was performed on the pathways list obtained for the human 
network gene list. In order to extract the top elements of each list for the rat-human 
comparison, rather than selecting an arbitrary threshold for p-values (i.e. p-value <0.05), we 
adopted a more sensitive approach. Using the rrho package in R, we identified the top n1 
elements in the rat pathway list and the top n2 in the human pathway list that resulted in 
the most significant overlap, where the significance was computed using the hypergeometric 
statistics. The value of n1 and n2 identified in this way were n1=106, n2=169, for an overlap 
of 67 terms (hypergeometric test p-value: 3.85x10-6).  
Statistical analysis 
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The hypergeometric statistic and the formula of the Fisher's method for combining p-values 
were computed in Excel 2010. The Kruskal Wallis test was implemented in Matlab as part of 
our signature identification method (Lauria, 2013). One-way and two-way ANOVA and Tukey 
post-hoc comparisons were performed with InVivoStat software (Clark et al, 2012). The 
effects of CMS were analyzed with Student’s t-test. Significance was assumed for p-
value<0.05. 
RESULTS 
Analysis of rat MDD models  
Different rat models of MDD sharing depression-like behaviors were investigated (Fig. 1A) 
within the GENDEP project. The analysis included FSL/FRL rats, FSL rats that experienced MS, 
LH/nLH, and SD/controls. In FRL/FSL/FSL+MS rats, depression-like responses were tested in 
the forced-swim test (Fig. S1). In LH rats, learned helplessness behavior was tested, thus the 
comparison was performed between rats showing resilient vs. susceptible response to stress 
exposure. In SD, experimental rats were exposed and defeated by a dominant male, while 
the controls were exposed to a novel cage.  
Identification of a transcriptomic signature in MDD models 
Transcriptomic profiling was performed in the hippocampus as neural plasticity is altered in 
this brain region in MDD patients and in models. The gene expression data were analyzed 
with a new bioinformatic tool designed to identify with high sensitivity a transcriptomic 
signature able to classify profiles from controls and disease models (Fig. 1A). The tool is 
based on a method previously developed by our group that identifies signatures by 
examining the rank of each gene in the individual expression profiles (Lauria, 2013; Lauria et 
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al, 2015). Interestingly, the tool identified a common transcriptomic signature comprising 70 
probesets (Table 1) able to separate controls from FSL and LH rats (Fig. 1B). In contrast, SD or 
MS were not separated by the transcriptomic signature (Fig. 1B). These findings suggest this 
experimental design allowed the identification of the common molecular dysregulations 
sustaining the susceptible response to stress which is responsible for generating depression-
like behaviors in the FSL and LH models, whereas this definite transcriptional response could 
not be detected in the SD group.  
Functional annotation of the transcriptional signature showed that ErbB (q-value=0.047) and 
TGF-β (q-value=0.056) contribute to the differential expression (Table S1).  
The algorithm used to identify the transcriptional signature has been designed to produce 
the shortest possible list while maintaining the highest classification accuracy. Therefore, we 
strived to expand the biological information present in a condensed form in the gene 
expression signature with the help of existing knowledge about biological processes as 
encoded in currently available protein interaction networks (Fig. 1A). We constructed a 
signature network of highly relevant proteins by carefully embedding the gene products 
belonging to the transcriptional signature (weighted by their p-values) into a literature–
derived protein-protein interaction network; the identified signature network included 272 
genes (Table S2). The functional annotation analysis highlighted the involvement of the 
ubiquitin-proteasome system (Fig. 2A; Tables S3-S4), which regulates cellular processes 
through degradation of specific functional proteins and controls synaptic plasticity, synaptic 
size, and energy metabolism. Functional annotation analysis also indicated the participation 
of the innate and adaptive immune responses, of ErbB receptors, of growth factor signaling, 
of leptin and insulin pathways, and of glutamatergic transmission (Fig. 2A; Tables S3-S4).  
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Identification of a transcriptomic signature in MDD patients 
While in healthy subjects allostatic plasticity mechanisms allow the development of an 
adaptive response to stressful experiences promoting resilience, in depressed patients 
changes in neural circuitry activated in response to stressors become “stuck” (McEwen, 
2017). This impairment of structural and functional allostatic plasticity characterizing 
depressed patients, which is particularly evident in the hippocampus, is shared by animal 
models of depression (McEwen et al, 2015). Therefore, we next examined whether evidence 
could be found that the same transcriptional dysregulations characterizing rat models play a 
relevant role in the human disease. For this purpose we employed the same bioinformatics 
tool to analyze transcriptomic profiles of depressed patients from data made available to 
researchers world-wide (Fig. 1A, Fig. S2). Remarkably, we could identify a transcriptional 
signature able to separate human MDD patients from controls, based on the expression of 
171 probesets (Table 2). The SCARA5 gene was common between the rat and human 
transcriptional signatures, with a combined p-value of 1.98x10-7 (Fisher's method applied to 
the p-values for the gene computed in the two datasets data-sets using the Kruskal-Wallis 
test). The Fth1 gene, which is included in the rat transcriptional signature (Table 1), is 
reported to interact with SCARA5 (Fig. S3), providing further evidence of the potential 
relevance of this pathway. Available data suggest that the expression of SCARA5 and its 
interacting genes Fth1 and Ftl1 are modulated by antidepressant treatment in mouse MDD 
models (Table S5). In addition, these genes are altered after immobilization stress, a model 
of posttraumatic stress disorder, and in female mice exposed to chronic mild stress (Table 
S5)  
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The response to antidepressant treatment was then investigated. Seven day treatment with 
ESC of LH and nLH revealed statistically significant effects in both Fth1 and Ftl1 levels for 
pharmacological treatment (two-way ANOVA, F(1,27)=29.19, p<0.0001; F (1,27)=18.20, 
p=0.0002, respectively), for the response to stress (F(1,27=8.34, p=0.0076; F(1,27)=20.72, 
p=0.0001, respectively), and for interaction (F(1,27)=5,21, p=0.031; F(1,27)=7.21, p=0.012, 
respectively) in the hippocampus. The expression of both genes was lower in LH rats 
(p=0.0048 and p<0.0001, respectively) and increased after ESC treatment (p<0.0001 and 
p=0.0002, respectively; Fig S4). Scara5 showed significant effects for the response to stress 
(F(1,27)=28.03, p<0.0001, Fig. S4). In the prefrontal cortex, Scara5 revealed a significant 
effect for the response to stress (F(1,29)=24.50, p<0.0001), treatment (F1,29)=5.69, 
p=0.024), and interaction (F(1,29)=72.13, p<0.0001); post hoc analysis showed a significant  
reduction after antidepressant administration (p=0.001, Fig. S4). Treatment effects were 
detected in both Fth1 and Ftl1 (F(1,28)=6.62, p=0.016; F(1,29)=31.65, p<0.0001, 
respectively), as well as stress effects (F(1,28)=54.43, p<0.0001; F(1,29)=45.49, p<0.0001, 
respectively) and an interaction effect was observed in Fth1 (F(1,28)=8.16, p=0.008). Both 
genes were down-regulated in LH rats (p=0.022; p=0.0006), whereas only Ftl1 was 
significantly up-regulated by ESC treatment (p=0.0043, Fig. 4S).  
In order to further investigate whether dyregulations of the Scara5 pathway are involved in 
the molecular underpinning of different MDD models, we compared the mRNA levels of 
these genes in the dorsal and ventral hippocampus of rats exposed to 7 weeks of CMS as 
compared to the respective controls. In the ventral hippocampus, decreased Scara5 mRNA 
levels were detected in CMS rats (-18%, t(23.129)=2.465, p=0.022, Fig. S5). In the dorsal 
hippocampus the decrease amounted to a similar extent, although the difference was not 
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statistically significant (-16%, t(16)=1.896, p=0.076, Fig. S5), possibly due to a lower number 
of samples. Fth1 and Ftl1 mRNA levels were not modulated by CMS exposure (Fig. S5). 
We next looked at the overlap between the genes belonging to the rat and human 
transcriptional signatures and expanded signatures with data from (Hyde et al, 2016). By 
taking the 10,000 most significant SNPs reported for the discovery dataset, we could identify 
333 genes mapped by a total 4177 SNPs. As shown in the Venn diagram (Fig. 2B, Fig. S6), 
three of the 333 genes were in common with the human signature genes (SPPL3, NHP2L1, 
ZBP1) and one gene with the rat signature (COL12A1), suggesting that the associated 
polymorphisms may influence gene expression. Two out of three human genes were also 
significantly modulated in the rat data-set, although at p-values that didn’t reach the cut-off 
needed to be included into the signature (NHP2L1: p = 1.49*10-4; ZBP1: p = 0.0475). We also 
compared the overlap with data from the new GWAS study by (Wray et al, 2018) and 
identified SPPL3 and CACNA1E, CACNA2D1, CTNND1, MLF1, PAX6 as common genes with the 
human signature and expanded signature, respectively (Fig. S6).    
Subsequently, the same workflow was followed for the analysis of the human signature (Fig. 
1A): it was subjected to functional annotation (Table S6) and a protein interaction network 
was constructed, which included 274 genes (Table S7). A comparison between rat and 
human networks revealed 25 overlapping genes (Table S7), with a probability of an overlap 
of this magnitude corresponding to p=6.80547x10-09 (Hypergeometric test). Functional 
analysis of the human signature network was then investigated (Fig. 2A, Tables S8-S9). 
Identification of overlapping enriched pathways between human and rat signature 
networks 
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The enrichments in GO terms and pathways in the signature network constructed from 
depressed patients’ data were compared with enrichments derived from the signature 
network generated from rat models. Notably, the comparison between the top enriched 
pathways in rat (n=169) and the top pathways in human (n=106) identified a highly 
significant overlap of 67 terms (p=3.85x10-6, Table 3). The common pathways confirmed the 
relevance of mechanisms observed in the GO enrichments, highlighting prominent roles for 
the ErbB pathway and for neurotrophin and other growth factors, chiefly FGF, VEGF, and IGF 
(Table 3). Other common pathways encompass the innate and adaptive immune responses; 
insulin and leptin signaling (Table 3). 
DISCUSSION 
Our study aimed to identify a hippocampal transcriptional signature that would discriminate 
affected animals from controls in MDD models, in the direction of investigating multiple 
models to capture the common mechanisms underlying shared symptoms (Akil et al, 2018). 
In hippocampus, the dysregulation of the adaptive allostatic response to stressors due to 
allostatic overload is linked with impaired plasticity, altered electrophysiological activity, and 
suppressed neurogenesis. Impairments due to allostatic overload are triggered by altered 
gene expression (McEwen et al, 2015). Our results show that rat models exhibiting many 
similar depression-like behaviors shared a common hippocampal transcriptional signature. 
Whereas the signature could distinguish FSL and LH models from controls, SD rats in our 
conditions did not display differential expression of the signature genes. This difference is 
likely due to the experimental design in this investigation. In our design, the FSL strain, a 
strain characterized by depressive-like behaviors, was the MDD model, whereas the FRL 
strain that does not show depressive-like behaviors served as control. Similarly, in the LH 
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model, the rats were tested for helpless behavior and animals displaying a helpless response 
were the MDD model group, whereas those who did not (nLH) were the controls. Therefore, 
in these two models the MDD model was represented by the susceptible group, which was 
compared with the controls, represented by the resilient group. However, we did not 
separate the resilient and susceptible SD animals following encounter with a dominant rat 
(Krishnan et al, 2007): they were treated as a single group in the comparison with the 
controls that were not exposed to the dominant rat. SD-resilient and susceptible mice have 
been shown to differ in transcriptional activity (Bagot et al, 2016; Krishnan et al, 2007), thus 
it is possible that in a different experimental design the transcriptional signature could 
discriminate between susceptible and unsusceptible SD rats. Overall, these results suggest 
that our transcriptional signature genes are specifically involved in the susceptibility to 
displaying depression-like responses and the lack of resilience skills. This interpretation could 
explain the significant pathway overlap that we detected between rat models and depressed 
patients, since resilience in the face of stress is a key aspect of a healthy response with 
respect to the development of MDD (McEwen et al, 2015). 
The rat and human transcriptional signatures shared the SCARA5 gene, which encodes for a 
scavenger receptor implicated in the innate immune response (Fig. S3) (Ojala et al, 2013). 
We speculate that SCARA5 differential expression contributes to the increased inflammatory 
response mediating the relationship between MDD and metabolic dysregulations (Stuart and 
Baune, 2012). SCARA5 is expressed at low but detectable levels in neuronal cells from 
human hippocampus (http://www.proteinatlas.org/ENSG00000168079-SCARA5/tissue). The 
discovery of SCARA5 association with MDD here reported is novel, although previous 
evidence for association with psychiatric disorders has been reported in a GWAS in 
schizophrenia (Xu et al, 2013) and in an infant trauma depression-like model, where the 
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alteration is reversed in the rescue phenotype (Rincón-Cortés et al, 2015). Moreover, 
increased transcriptome variability of SCARA5 was observed in temporal cortex of autistic 
subjects (Garbett et al, 2008). We can speculate that this pathway participates in the crucial 
role of scavenger receptors in microglia inflammatory response, which is recognized in 
Alzheimer’s disease (Cornejo et al, 2017; Frenkel et al, 2013), but is also important in MDD 
(Brites and Fernandes, 2015); further studies are needed to confirm our results. 
We investigated the biological meaning of rat and human signatures by network 
reconstruction and gene functional annotation and identified numerous common pathways 
between MDD patients and FSL/LH models. Enrichment analysis suggested the 
pathophysiological significance of ErbB/neuregulin signaling. The ErbB family comprises four 
growth factor receptors that bind neuregulin and related EGF domain-containing proteins 
implicated in neural development, neurotransmission and synaptic plasticity (Mei and Nave, 
2014). Several ErbB/neuregulin members have been associated with MDD (Mei and Nave, 
2014). Genetic neuregulin variants were associated with a distinct pattern of the association 
between symptom severity and psychotic symptoms in depressed patients (Bousman et al, 
2014). Reduced ErbB3 and neuregulin-1 levels have been detected in MDD patients in brain 
and leukocytes (Aston et al, 2005; Milanesi et al, 2012). Neuregulin-1 has also been 
implicated in the response to antidepressant treatment in genetic analyses in humans and in 
animal models (Biernacka et al, 2015; Wang et al, 2014). Our results supporting the 
hypothesis that altered levels of neuregulin/ErbB members in allostatic overload conditions 
play a role in the development of depressive behaviors are corroborated by findings in 
chronic mild stress rats, where neuregulin/ErbB signaling shows a dysregulation reversed by 
antidepressant treatment (Dang et al, 2015).  
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In addition, the relevance of other growth factor pathways was demonstrated in rat and 
human networks. In particular, enriched neurotrophic factor pathways have been identified, 
consistent with a large body of literature showing that BDNF levels are altered in depressed 
patients (Molendijk et al, 2014), that the BDNFVal66Met polymorphism interacting with 
stress exposure is associated with MDD (Hosang et al, 2014) and that neurotrophic signaling 
is instrumental for antidepressant efficacy (Björkholm and Monteggia, 2016). These findings 
confirm the hypothesis that stress decreases BDNF expression, thus impairing neurogenesis 
and neural plasticity activated in the resilient response to stress (Autry and Monteggia, 2012; 
Gray et al, 2013; McEwen et al, 2015). Moreover, we discovered dysregulations in FGF, IGF-
1, and VEGF, which have been recently associated with MDD (Sharma et al, 2016; Turner et 
al, 2016). It is especially suggestive that work from the Pritzker Neuropsychiatric Disorder 
Research Consortium allowed the important discovery that FGF, originally implicated in 
neural development, plays a crucial role in neurogenesis and in neuroplasticity in adulthood, 
suggesting a neuromodulatory function in anxiety-like and depression-like behaviors 
(Aurbach et al, 2015; Turner et al, 2016), providing support for our findings. In addition, 
altered levels of FGF family members were revealed in MDD patients, both in blood and in 
brain (Wu et al, 2016). Altered levels of IGF-1, a neurotrophic, neurogenetic and 
neuroprotective factor, were repeatedly reported in MDD patients, although with conflicting 
results in the direction of change (Sharma et al, 2016). In MDD models, IGF administration 
produced antidepressant-like effects (Burgdorf et al, 2016), in line with our findings. VEGF 
exerts direct and indirect neurogenetic effects that have been linked with antidepressant 
activity (Fournier and Duman, 2012). A role in MDD is also supported by the data showing 
that peripheral VEGF levels are significantly elevated in MDD patients (Carvalho et al, 2015; 
Sharma et al, 2016). Overall, our findings corroborate the hypothesis suggested by a body of 
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recent results that modulations of the NGF, FGF, IGF, and VEGF pathways contribute to the 
molecular underpinning of MDD probably by hampering the adaptive neuroplasticity 
responses associated with resilient responses to stressors. 
We observed a considerable impact on metabolic pathways, including insulin and leptin 
signaling. Compelling evidence supports the involvement of a metabolic component in the 
pathophysiology of MDD. A high degree of co-morbidity between MDD and type-2 diabetes 
was demonstrated (Stuart and Baune, 2012), with insulin resistance as a connecting link 
(Bigio et al, 2016; Nasca et al, 2013). In agreement with our findings, elevated plasma insulin 
levels were observed in depressed patients (Domenici et al, 2010; Lamers et al, 2016), the 
hypoglycemic agent pioglitazone displayed antidepressant efficacy (Kemp et al, 2012) and 
decreased insulin signaling induced depression-like behaviors in rats (Grillo et al, 2011). In 
line with our results, altered leptin levels have been repeatedly observed in MDD patients 
(Lamers et al, 2016) and leptin-mediated antidepressant-like effects reported in animal 
models (Bigio et al, 2016; McEwen, 2017; Stieg et al, 2015).  
It has been proposed that the mechanistic link in the bi-directional relationship between 
MDD and T2DM is the activation of the inflammatory response associated with both 
disorders (Stuart and Baune, 2012). Our study revealed a transcriptional dysregulation 
involving immune responses both in patients and in animal models. Moreover, an affected 
gene (ZBP1) in common with the recent GWAS for MDD (Hyde et al, 2016) is reported to play 
a role in the innate immune response. Thus, our data are consistent with the hypothesis that 
there is a link between metabolic dysregulations and inflammatory components in MDD. 
Limitations of this study are that hippocampal sub-regions could not be differentiated, 
whereas distinct plasticity responses are evoked in hippocampal sub-fields. Moreover, the 
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experimental design did not discriminate SD-susceptible and resilient rats, preventing an 
appropriate comparison of this model. The number of patients was relatively small and no 
characterization was possible. Therefore, testing the relevance of the identified genes and 
pathways in additional animal models and human subjects is required in future experiments. 
Crucially, further experiments are necessary to elucidate the role of SCARA5 in MDD 
pathophysiology, here revealed for the first time.  
In conclusion, the present results demonstrate that both MDD patients and the FSL and LH 
models show dysregulations in growth factor signaling, in metabolic pathways, and in 
inflammatory responses. MDD arises when the resilience of healthy brains is lost and instead 
of promoting neural circuitry adaptation able to cope with stressors, a maladaptive plasticity 
takes place (McEwen, 2017). Compelling evidence supports the crucial contribution provided 
by inappropriate activation of these pathways through gene expression regulation and 
epigenetic mechanisms finally impairing the mechanisms for a resilient response to stress 
exposure and leading to allostatic overload (Bigio et al, 2016; Gray et al, 2013; Nasca et al, 
2013). Lastly, and speculatively, the molecular alterations identified in the present study 
could contribute to the identification of molecular alterations characterizing MDD biotypes 
recently identified by functional magnetic resonance imaging (Drysdale et al, 2016).  
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FIGURE LEGENDS 
Figure 1. A: Schematic representation of the workflow. The hippocampi of rat models of 
MDD were subjected to transcriptional analysis. Gene expression data were analyzed with a 
recently established algorithm for signature-based clustering of expression profiles. Network 
analysis was then used to expand the list of signature genes with the help of protein-protein 
interactions from the literature and the gene list was functionally annotated. Subsequently, 
the same workflow tool was applied to transcriptomic data from human MDD patients and 
respective controls. B: Classification of different models of MDD in rats. The graph 
represents sample classification by means of the rat transcriptional signature. Nodes 
represent rat samples and the length of connecting edges is proportional to the degree of 
similarity between the samples according to their transcriptional signature (short edges 
connect samples with similar signature, missing edges indicate negligible similarities). Based 
on the identified transcriptional signature (Table 1), all the models of MDD in rats were 
separated from control subjects except the SD model. Node colors and IDs indicate the 
considered rat models of MDD: FSL (Flinders Sensitive Line), FSL+MS (Flinders Sensitive Line 
with Maternal Separation), LH (Learned Helplessness), SD (Social Defeat), FRL (Flinders 
Resistant Line), CTRL_LH (control rats of the LH dataset) and CTRL_SD (control rats of the SD 
dataset). 
Figure 2. A: Schematic graphs of over-represented Gene Ontology biological process terms in 
human or rat networks respectively. GO terms are represented as nodes, and the strongest 
GO term pair-wise similarities are designated as edges in the graph. GO terms overlapping in 
the human and rat networks are grouped. Colors and node size represent the p-values (low 
values in red and big size, high in green and small size). Complete lists of GO terms can be 
33 
 
found in Tables S3 and S8). B: Overlap between genes belonging to the rat and human 
transcriptional signatures and the genes where the top 10,000 most significant SNPs in the 
discovery dataset of the MDD GWAS are located (4177 SNPs falling within 333 genes (Hyde 
et al, 2016)). 
Table 1. Transcriptional signature from hippocampal gene expression in rat MDD models  
Transcriptional signature length 70
Validation scheme 10-fold cross-validation
Accuracy of predictions (training set) 100.00%
Accuracy of predictions (validation set) 99.64%
Permutation test p-value (100 trials) 0
Filtering statistical test Kruskal-Wallis
Threshold p-value for filtering 3.18E-05
Probe ID Associated gene symbol p-value FSL/CTRL FSL+MS/CTRL LH/CTRL SD/CTRL 
1367552_at Svs4 1.67E-05 down down down up 
1367565_a_at Fth1 1.90E-05 down down up down 
1367641_at Sod1 8.58E-07 up up up down 
1368282_at Dpep1 1.67E-05 down down down up 
1368543_at Nox4 2.12E-05 down down down up 
1368714_at Prl8a2 2.25E-05 down down down up 
1368785_a_at Pitx2 1.40E-05 up up down up 
1369110_x_at RT1-EC2 2.68E-05 down down down up 
1369260_a_at Mpp4 5.61E-06 up up up down 
1369581_at Pemt 3.50E-06 up up down down 
1369876_at Gnb3 1.10E-05 down down down up 
1369948_at Ngfrap1 1.48E-05 up up up down 
1370041_at Stmn2 2.99E-05 up up up down 
1370106_at Fgf18 1.41E-06 up up up down 
1370702_at Gabrr3 1.67E-05 down down down up 
1370888_at Cox5a 8.85E-07 up up up down 
1370902_at Akr1b8 1.28E-06 up up down down 
1370971_at Myh1 /// Myh2 3.39E-06 down down down up 
1370987_at Spn 1.72E-05 up up up down 
1371112_at Ret 7.24E-11 up up down down 
1371170_a_at Il1a 1.05E-06 up up down down 
1371211_a_at Nrg1 2.46E-06 up up down down 
1371224_a_at Drp2 9.46E-06 down down down down 
1371304_a_at Myl6 /// Myl6b /// Myl6l 2.87E-07 up up up down 
1371323_at Ndufa4 5.10E-06 up up up down 
1371542_at Tuba4a 2.79E-06 up up up down 
1371566_at Fbxl22 2.68E-05 up up down down 
1373571_at Rtn3 6.09E-10 down down up down 
1374302_at Opn4 1.04E-05 down down down up 
1377502_at Foxo1 3.00E-05 up up up down 
1379435_at Dguok 1.23E-07 down down down down 
1381039_at Dnah1 2.38E-05 up up up down 
1381650_at Sephs1 9.93E-08 down down down up 
1382337_at Stap1 2.38E-05 down down down up 
1382590_at Rftn1 2.06E-05 up up up down 
1382852_at Rnf190 1.43E-08 down down down up 
1384143_at Cgn 7.41E-06 up up down down 
1384707_at Scara5 3.18E-05 up up down down 
1384852_at Rab27a 1.21E-05 up up up down 
1385019_at Bank1 3.85E-06 up up down down 
1385452_at Fbln1 7.18E-06 up up down down 
1385510_at Ttll13 1.18E-08 down down down up 
1386004_s_at Morf4l1 3.66E-07 down down down down 
1387123_at Cyp17a1 3.18E-06 up up down down 
1387488_a_at Calcr 5.61E-06 down down down down 
1387522_at Rhag 2.12E-05 down down down up 
1387539_at Si 8.37E-06 up up down down 
1387544_at Mk1 1.53E-05 down down down up 
1387762_s_at Jund 5.74E-07 down down down up 
1387862_at Ywhaq 4.62E-06 down down up down 
1388033_at Cxcl3 2.99E-05 up up down up 
1388370_at Ccni 1.96E-06 down down up down 
1388961_at Itgb1bp2 3.28E-06 up up down down 
1389987_at Trib1 4.51E-07 up up down down 
1390140_at Lemd3 9.76E-06 up up down down 
1391156_at Podnl1 6.79E-07 up up down down 
1391887_at Igsf9 2.63E-06 up up down down 
1392250_at Anxa2 1.17E-05 up up down down 
1392384_s_at Akr1d1 4.47E-06 up up down up 
1392796_at Cnot6l 2.67E-05 up up down up 
1393489_at Rsb66 2.88E-09 up up up down 
1395016_at Andpro 1.10E-05 down down down up 
1395126_at Fcrls 6.62E-09 down down down up 
1395580_at Col12a1 1.28E-05 up up down down 
1396766_at Ift81 2.25E-05 up up up down 
1398287_at Plau 1.94E-05 up up down down 
1398478_at Mlh3 2.63E-06 up up up down 
1398623_at Chrnb4 8.60E-07 up up up down 
1398767_at Ubc 3.65E-09 down down down down 
1398860_at Nedd8 2.81E-05 up up up down 
 
Table 2. Transcriptional signature from hippocampal gene expression in human 
depressed patients 
Transcriptional signature length 171
Validation scheme 10-fold cross-validation
Accuracy of predictions (training set) 100.00%
Accuracy of predictions (validation set) 100.00%
Permutation test p-value (100 trials) 0
Filtering statistical test Kruskal-Wallis
Threshold p-value for filtering 7.85E-03
Probe ID Associated gene symbol p-value MDD/CTRL 
1552604_at C21orf74 5.03E-03 down 
1552769_at ZNF625 5.56E-03 down 
1553423_a_at SLFN13 2.39E-03 up 
1553479_at TMEM145 6.80E-03 down 
1553488_at TEKT5 2.14E-03 up 
1553726_s_at C6orf170 2.67E-03 up 
1553900_s_at POM121L1P /// 
POM121L8P /// 
POM121L9P 
4.53E-03 
up 
1554086_at TUBGCP3 5.56E-03 up 
1554246_at C1orf210 5.56E-03 down 
1554354_at SIAE 3.31E-03 up 
1554572_a_at SUV39H2 4.53E-03 up 
1554705_at SCARA5 3.21E-04 up 
1555394_at PIGK 7.51E-03 up 
1555412_at FBXL21 5.03E-03 up 
1555446_s_at TRAPPC10 2.67E-03 down 
1555555_at BBS9 1.72E-03 down 
1555648_at FOXP2 1.92E-03 up 
1556581_at ZNF778 3.68E-03 down 
1557701_s_at POLH 7.51E-03 down 
1558253_x_at ZNF587 7.51E-03 down 
1558425_x_at NCRNA00265 7.51E-03 down 
1558517_s_at LRRC8C 6.15E-03 down 
1558915_a_at PEX14 4.53E-03 down 
1558995_at ZNF547 1.72E-03 down 
1559092_at SLC9A5 4.53E-03 up 
1561238_at PEX2 2.67E-03 down 
1562392_at MRPL23 6.15E-03 up 
1562484_at C17orf104 6.75E-04 down 
1562633_at RMST 5.98E-04 down 
1564707_x_at GLS2 1.37E-03 up 
1565603_at PWP2 5.56E-03 up 
1565716_at FUS 1.53E-03 down 
1566269_at RALGAPA1 2.67E-03 down 
1567623_at ABLIM2 7.61E-04 down 
1568734_a_at HS1BP3 1.92E-03 down 
1569583_at EREG 4.53E-03 up 
1570020_at AACSP1 7.51E-03 up 
200596_s_at EIF3A 1.72E-03 down 
202494_at PPIE 4.53E-03 up 
202769_at CCNG2 5.56E-03 up 
203036_s_at MTSS1 5.03E-03 down 
203980_at FABP4 6.15E-03 up 
204665_at SIKE1 2.14E-03 up 
204901_at BTRC 7.14E-03 down 
205100_at GFPT2 7.51E-03 down 
205315_s_at SNTB2 4.53E-03 down 
205428_s_at CALB2 4.53E-03 down 
205994_at ELK4 4.09E-03 down 
206088_at LRRC37A3 6.80E-03 up 
206254_at EGF 3.21E-04 up 
206276_at LY6D 3.68E-03 up 
206331_at CALCRL 6.15E-03 down 
206524_at T 6.15E-03 up 
206642_at DSG1 3.31E-03 up 
207187_at JAK3 7.51E-03 up 
207682_s_at KIF25 3.31E-03 up 
208021_s_at RFC1 5.03E-03 up 
208095_s_at SRP72 5.56E-03 down 
209365_s_at ECM1 1.37E-03 down 
210304_at PDE6B 2.14E-03 up 
210474_s_at CDK11A /// CDK11B 5.29E-03 up 
210503_at MAGEA11 1.68E-04 up 
210855_at GREB1 1.53E-03 up 
210937_s_at PDX1 7.61E-04 up 
211131_s_at EDA 4.30E-03 down 
211422_at TRPM3 5.56E-03 up 
211488_s_at ITGB8 3.31E-03 down 
211639_x_at IGHA1 /// IGHA2 /// 
IGHD /// IGHG1 /// 
IGHG3 /// IGHG4 /// 
IGHM /// IGHV4-31 /// 
IGHV4-59 /// 
LOC100126583 
5.56E-03 
up 
211789_s_at MLXIP 3.68E-03 down 
212658_at LHFPL2 3.68E-03 down 
212675_s_at CEP68 3.88E-03 up 
213546_at DKFZP586I1420 5.56E-03 down 
213956_at CEP350 5.03E-03 down 
214275_at MED12 6.80E-03 up 
214561_at LILRP2 4.53E-03 up 
214652_at DRD1 7.51E-03 up 
214677_x_at IGLV1-44 /// 
LOC100290481 
2.14E-03 
up 
214982_at SNRNP200 1.22E-03 up 
215105_at CG030 9.65E-04 down 
215168_at TIMM17A 1.68E-04 down 
215272_at OGG1 2.39E-03 up 
215702_s_at CFTR 1.53E-03 up 
216258_s_at SERPINB13 3.68E-03 down 
216454_at TRMT1 2.14E-03 up 
216504_s_at SLC39A8 5.56E-03 up 
216734_s_at CXCR5 3.68E-03 up 
217326_x_at TRBC2 3.68E-03 down 
217478_s_at HLA-DMA 7.51E-03 down 
217594_at ZCCHC11 2.67E-03 up 
218587_s_at POGLUT1 7.51E-03 down 
218795_at ACP6 4.53E-03 up 
218819_at INTS6 6.15E-03 down 
218994_s_at STAG3L4 7.16E-04 down 
219426_at EIF2C3 3.21E-04 down 
219430_at GPR137 6.80E-03 up 
219576_at MAP7D3 6.15E-03 down 
219577_s_at ABCA7 5.56E-03 up 
219699_at LGI2 6.80E-03 down 
220120_s_at EPB41L4A 2.67E-03 up 
220393_at LGSN 6.80E-03 down 
220649_at AGBL3 6.15E-03 up 
221201_s_at ZNF155 7.51E-03 down 
221211_s_at C21orf7 2.67E-03 down 
221416_at PLA2G2F 4.53E-03 down 
221439_at RBBP9 4.77E-03 up 
221672_s_at TRAPPC9 6.80E-03 up 
221744_at DCAF7 8.58E-04 up 
222597_at SNAP29 5.56E-03 up 
222876_s_at ADAP2 2.97E-03 down 
223149_s_at PTPN23 1.92E-03 up 
223329_x_at SUGT1 2.67E-03 down 
223344_s_at MS4A7 5.03E-03 down 
223520_s_at KIF13A 5.56E-03 up 
223761_at FGF19 5.03E-03 down 
223791_at FAM27A /// FAM27B /// 
FAM27C 
5.03E-03 
down 
224320_s_at MCM8 6.80E-03 up 
224454_at ETNK1 6.75E-04 up 
224638_at SPPL3 6.80E-03 up 
224998_at CMTM4 7.51E-03 up 
225083_at GTF3C6 2.67E-03 down 
225274_at PCYOX1 2.03E-03 up 
225407_at MBP 1.92E-03 up 
225638_at C1orf31 6.15E-03 down 
226126_at TBCK 3.68E-03 down 
227038_at SGMS2 2.39E-03 up 
227228_s_at CCDC88C 7.51E-03 up 
227666_at DCLK2 5.56E-03 up 
227939_s_at TRA2A 2.97E-03 down 
228096_at C1orf151 7.51E-03 down 
228404_at IRX2 7.51E-03 up 
229332_at HPDL 5.56E-03 up 
229485_x_at SHISA3 3.68E-03 down 
230443_at NHP2L1 6.80E-03 up 
230662_at RNF187 2.14E-03 up 
231080_at CDAN1 3.21E-04 up 
231641_at FLJ10213 4.09E-03 down 
231683_at GLYAT 3.68E-03 up 
231755_at IL1F8 6.15E-03 down 
231763_at POLR3A 7.51E-03 up 
232216_at YME1L1 1.92E-03 down 
232901_at RARS2 1.53E-03 up 
233517_s_at HIF3A 7.51E-03 up 
233669_s_at TRIM54 1.22E-03 up 
234280_at REG3A 1.72E-03 up 
234700_s_at RNASE7 6.15E-03 down 
234730_s_at RIPK4 6.15E-03 up 
234818_at TMEM108 7.51E-03 up 
234927_s_at MAGIX 6.15E-03 up 
235582_at E2F2 5.56E-03 down 
238222_at GKN2 7.51E-03 down 
238659_at KIAA0141 3.31E-03 up 
238761_at ELK4 2.14E-03 down 
238974_at C2orf69 7.50E-03 up 
238990_x_at TRIM61 1.53E-03 down 
239084_at SNAP29 3.68E-03 up 
239148_at MARVELD3 6.75E-04 up 
239247_at NCRNA00103 6.80E-03 down 
239617_at GHRLOS 1.37E-03 up 
240883_at PFKFB1 1.53E-03 up 
241025_at UTP6 3.31E-03 up 
241280_at ALDOB 2.67E-03 down 
241862_x_at C19orf45 6.15E-03 down 
242020_s_at ZBP1 4.53E-03 up 
242065_x_at IDI1 4.09E-03 up 
242539_at DIS3L2 2.39E-03 down 
242587_at SLC9A9 4.09E-03 down 
242634_at GATAD1 7.51E-03 down 
243076_x_at GLI4 2.97E-03 up 
244526_at RASGRP3 1.47E-04 down 
244717_x_at SV2B 1.22E-03 down 
65630_at TMEM80 6.15E-03 up 
 
Table 3. Common pathways between human patients and rat models 
Pathway logQ (human)
Signaling by EGFR 47.19399645
MAPK signaling pathway - Homo sapiens (human) 34.9829695
Developmental Biology 31.77920881
EGFR downregulation 31.51105843
NGF signalling via TRKA from the plasma membrane 31.09902222
Signalling by NGF 30.68505372
VEGFA-VEGFR2 Pathway 29.09387805
Signaling by VEGF 28.52532641
Signaling by FGFR1 26.31881238
Signaling by FGFR3 26.31881238
Signaling by FGFR4 26.31881238
Signaling by FGFR 26.30520623
Signaling by FGFR2 26.30520623
DAP12 signaling 25.47372941
Downstream signal transduction 24.71667478
DAP12 interactions 24.56440711
Signaling by ERBB2 23.95878086
Downstream signaling of activated FGFR1 23.78281148
Downstream signaling of activated FGFR2 23.78281148
Downstream signaling of activated FGFR3 23.78281148
Downstream signaling of activated FGFR4 23.78281148
Signaling by PDGF 23.40080147
Signaling by SCF-KIT 23.11476713
Immune System 22.88275437
Fc epsilon receptor (FCERI) signaling 22.48300794
Adaptive Immune System 20.96292751
Innate Immune System 20.59279339
Insulin receptor signalling cascade 18.99666088
Interleukin-3, 5 and GM-CSF signaling 18.73475295
VEGFR2 mediated cell proliferation 18.73475295
Signaling by Interleukins 18.61942963
Signaling by ERBB4 18.53012544
Ras signaling pathway - Homo sapiens (human) 18.52724169
IRS-mediated signalling 18.32920801
Signaling by the B Cell Receptor (BCR) 18.275547
Signaling by Insulin receptor 18.15502257
IGF1R signaling cascade 18.10314514
IRS-related events triggered by IGF1R 18.10314514
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) 18.10314514
Cytokine Signaling in Immune system 17.32668866
Interleukin receptor SHC signaling 17.1451683
Interleukin-2 signaling 16.64797728
FCERI mediated MAPK activation 16.40952973
Signaling by Leptin 15.43225358
MAPK family signaling cascades 15.33723586
FRS-mediated FGFR1 signaling 15.0335407
FRS-mediated FGFR2 signaling 15.0335407
FRS-mediated FGFR3 signaling 15.0335407
FRS-mediated FGFR4 signaling 15.0335407
Frs2-mediated activation 14.77520543
Pathways in cancer - Homo sapiens (human) 14.74480642
MAPK1/MAPK3 signaling 14.71797908
Prolonged ERK activation events 14.65606827
Signal Transduction 14.32549614
GRB2 events in EGFR signaling 14.23653572
GRB2 events in ERBB2 signaling 14.23653572
RAF/MAP kinase cascade 14.23653572
SHC1 events in EGFR signaling 14.23653572
SHC1 events in ERBB2 signaling 14.23653572
SHC1 events in ERBB4 signaling 14.23653572
SOS-mediated signalling 14.23653572
Signalling to ERKs 14.12045982
Disease 13.99833897
ARMS-mediated activation 13.99833897
Signalling to p38 via RIT and RIN 13.99833897
Signalling to RAS 13.68633912
Diseases of signal transduction 13.61501046

Human Rat 
A 
B 
human signature - rat signature: SCARA5 
GWAS in MDD - rat signature: COL12A1 
GWAS in MDD - human signature: SPPL3, NHP2L1, ZBP1 
